Articles By Rob Wright, Chief Editor
Allogene Therapeutics — The Juggernaut Built On Kite’s Flight
David Chang, M.D., Ph.D., CEO and cofounder of Allogene Therapeutics, shares how the successful exit from Kite Pharma (acquired by Gilead for $11.9 billion in 2017) led to the building of Allogene, a $3.4 billion clinical-stage biopharma developing allogeneic CAR-T therapy.
Why John Sculley Views Healthcare As His “Noble Cause”
John Sculley, the former CEO of Apple who is now an entrepreneur and investor in high-tech startups, discusses where he sees opportunity in the healthcare industry, along with the leaders he views as being just as visionary as Steve Jobs, if not more so.
What Biopharmas Could Learn About Reinvention — From Outsiders
The biopharmaceutical industry is no stranger to the concept of reinvention. It’s all part of innovation. But reinvention can apply to people, too, and this month we profile two businessmen who took on some significant risk to change their paths.
JPM Welcomes Life Sciences Into What Could Be The Roaring Twenties Of Discovery
Rob Wright shares his thoughts on the 38th Annual J.P. Morgan Healthcare Conference and “JPM” as we enter a decade that could be “roaring with cures.” Content specifically curated for professional development of c-level life science leaders.
The Leadership Meeting – Where Leaders Go To Learn
Rob Wright provides a high-level overview of The Leadership Meeting, a pre-JPM conference with content specifically curated for professional development of c-level life science leaders.
Can You Help With Gender Diversity In The New Year?
Despite a banner year for Life Science Leader having diversity well represented on its covers, chief editor Rob Wright admits there is more work to be done and seeks help from readers in connecting to more diverse leaders of biopharma.
J&J And Merck Detail How They Are Investing For Impact
Two Big Pharma executives explain how their organizations are investing for impact.
The 5-Step Strategy That Saved Genmab From A Dire Outlook
Jan G. J. van de Winkel, Ph.D., cofounder, president, and CEO since 2010, remembers when Genmab faced some pretty tough decisions.
Brightspot: How A Biopharma VC Makes A Difference For Orphans
Ed Torres, managing partner at Lilly Ventures, shares how he and his wife got involved in making a difference for U.S. orphans.